Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor (Nasdaq: DXR) announced that President and CEO Michael Feldschuh will meet institutional investors at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.
Mr. Feldschuh will be available for one-on-one investor meetings and will meet with senior Maxim analysts; participation in the summit is by invitation. Institutional investors seeking meetings are directed to contact Bret Shapiro, COO – Head of Capital Markets, COREIR, via phone (561)-479-8566 or email brets@coreir.com. For the full summit agenda visit www.maximgrp.com/2025-growth-summit.
Daxor (NASDAQ: DXR) will exhibit at the MedAxiom Cardiovascular Transforum Fall'25 at the JW Marriott Austin from October 16–18, 2025. The company plans to debut its next‑generation BVA diagnostic system and demonstrate how the technology addresses hospital readmissions and resource optimization for cardiovascular providers. CEO Michael Feldschuh said the launch is expected to accelerate sales momentum and support wider commercial adoption by connecting with cardiovascular innovators.
The appearance positions Daxor to showcase clinical and operational benefits to health systems and potential customers attending the conference in Austin, TX.
Daxor Corporation (Nasdaq: DXR) unveiled its newly FDA-cleared next-generation Blood Volume Analysis (BVA) analyzer at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The new system features enhanced ease of use, speed, and over 95% accuracy.
Three pivotal studies from leading institutions validated BVA technology's effectiveness: Banner University Medical Center reported zero unplanned hospital admissions for optimally managed patients, Wellstar Health System demonstrated improved LVAD outcomes with increased survival rates and reduced readmissions, and Geisinger Medical Center confirmed BVA's utility in diagnosing Cardiac Amyloidosis.
Daxor Corporation (Nasdaq: DXR), the leader in blood volume measurement technology, will showcase its newly FDA-cleared next-generation blood volume analyzer (BVA) at the Heart Failure Society of America Annual Scientific Meeting from September 26-29, 2025.
The new BVA system represents a significant technological advancement, being three times faster than the previous BVA-100™ model, requiring 50% less blood drawn from patients, and maintaining over 95% accuracy with a portable, battery-operated design. New clinical data validating BVA technology will be presented, including research from Wellstar Medical Group and Banner University Medical Center focusing on heart failure patient outcomes.
Daxor Corporation (Nasdaq: DXR) announced significant findings from a new pilot study published in the Journal of Critical Care, validating their Blood Volume Analysis (BVA) technology for COVID-19 and sepsis patients. The study revealed that 48% of COVID-19 patients were incorrectly assessed for fluid status by clinicians, highlighting the critical need for more accurate measurement tools.
The research demonstrated that sepsis patients showed higher albumin transudation rates compared to COVID-19 patients, indicating more severe blood vessel integrity breakdown. The study coincides with Daxor's recent FDA clearance in August 2025 for their new rapid BVA system, which is three times faster than their previous BVA-100™ analyzer while maintaining 95% accuracy.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO and President Michael Feldschuh will deliver a presentation that will be available on-demand starting September 5, 2025, at 7:00 a.m. ET.
The conference will take place from September 8-10, 2025 at the Lotte New York Palace Hotel. Registered conference investors can schedule one-on-one meetings with Mr. Feldschuh and access the presentation through the conference registration portal.
Daxor Corporation (Nasdaq: DXR), the leader in blood volume measurement technology, released a mid-year shareholder update highlighting significant achievements in 2025. The company secured FDA clearance for its new rapid, lightweight Blood Volume Analysis System in August 2025, which is three times faster and more portable than its predecessor BVA-100.
Financial highlights include a 73% increase in unaudited revenues for H1 2025 compared to H1 2024, driven by diagnostic kit sales and military contracts. The company's net assets grew to $36.6 million, with NAV increasing to $7.15 per share, up $0.40 from June 2024.
Clinical validation strengthened with multiple studies, including research showing 2.61 times better survival in BVA-identified euvolemic heart failure patients. The company expanded market adoption with multiple new facility adoptions across the U.S. in 2025.
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, has made available the replay of its Nasdaq Closing Bell Ceremony from August 8, 2025. The ceremony celebrated a significant milestone: the FDA 510(k) clearance for the company's new Daxor BVA™ (Blood Volume Analyzer).
The next-generation device is characterized as a patent-pending, rapid, compact, and hand-held blood volume measurement system designed for lab-based use.
Daxor Corporation (NASDAQ: DXR) has received FDA 510(k) clearance for its next-generation Blood Volume Analyzer (BVA), a revolutionary diagnostic device for precise fluid management. The new hand-held, lab-based system offers significant improvements over its predecessor, being 3x faster and weighing only 7 pounds.
The device addresses critical healthcare challenges across multiple conditions, including heart failure, critical care, and sepsis. Clinical studies have shown remarkable results, with BVA-guided care reducing heart failure mortality by 86% and demonstrating 66% lower mortality in ICU patients. The system also helped achieve 56% fewer hospital readmissions and shorter hospital stays.
Developed in collaboration with the U.S. Department of Defense, the technology builds on Daxor's extensive experience with over 75,000 tests shipped and 50 years of research.
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the adoption of its Blood Volume Analysis (BVA) technology by three new hospitals. The expansion includes both the company's CLIA-certified ezBVA Lab service and on-site blood volume analyzers.
The new facilities include a Tennessee medical center adopting ezBVA Lab services for cardiology, a major Arkansas hospital implementing an on-site analyzer, and a leading referral hospital serving Arizona, Nevada, and Utah utilizing the ezBVA Lab service for heart failure patients. The company expects continued sales growth throughout 2025 as clinicians increasingly recognize BVA's benefits for optimizing fluid management.